Phaseline

Targets › GSPT1

GSPT1 (Eukaryotic peptide chain release factor GTP-binding subunit ERF3A): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

GTPase component of the eRF1-eRF3-GTP ternary complex, a ternary complex that mediates translation termination in response to the termination codons UAA, UAG and UGA. GSPT1/ERF3A mediates ETF1/ERF1 delivery to stop codons: The eRF1-eRF3-GTP complex binds to a stop codon in the ribosomal A-site. GTP hydrolysis by GSPT1/ERF3A induces a conformational change that leads to its dissociation, permitting ETF1/ERF1 to…. (UniProt, P15170)

Open in Phaseline: the race on GSPT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Monte Rosa TherapeuticsMRT-2359
GSPT1 molecular glue degrader
GSPT1Phase 2Castration-Resistant Prostate Cancer (CRPC); NSCLCDec 2026

Conditions

Castration-Resistant Prostate Cancer (CRPC) (1) NSCLC (1)

Modalities

small molecule (1)

Companies

Monte Rosa Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.